bendamustine hydrochloride has been researched along with pci 32765 in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (57.63) | 24.3611 |
| 2020's | 25 (42.37) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, S | 1 |
| Chanan-Khan, AA; Hallek, M; Howes, A; Kay, NE; Mahler, M; Osterborg, A; Salman, M; Sun, S; Wan, Y; Zhuang, SH | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Blum, KA; Byrd, JC; Christian, B; Flynn, J; Jaglowski, S; Jenkins, C; Jones, JA; Lozanski, G; Maddocks, K; Porcu, P; Wei, L | 1 |
| Herishanu, Y; Katz, BZ | 1 |
| Molica, S | 1 |
| Balakrishnan, K; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Wierda, WG; Woyach, JA | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Treon, SP | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Hagiwara, K; Iida, H; Nagai, H; Tokunaga, T | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR | 1 |
| Augustson, B; Brown, R; Gibson, J; Grigoriadis, G; Harrison, S; Ho, JP; Horvath, N; Jaksic, W; Johnston, A; Joshua, D; Kalff, A; Kalro, A; Lee, C; Mollee, P; Prince, HM; Quach, H; Roberts, AW; Spencer, A; Szer, J; Talaulikar, D; Tam, CS; Trotman, J; Ward, C; Zannettino, A | 1 |
| Andrasiak, I; Knopinska-Posluszny, W; Rybka, J; Wrobel, T | 1 |
| Baculea, S; Cote, S; Mealing, S; Singh, M; Whelan, J | 1 |
| Chan, EKH; Chanan-Khan, A; Cramer, P; Diels, J; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Howes, A; Janssens, A; Loscertales, J; Mahler, M; Rule, S; Salman, M; Santucci-Silva, R; Sengupta, N; Traina, S | 1 |
| Appleton, S; Burton, C; Howell, D; Johnson, R; Patmore, R; Roman, E; Smith, A | 1 |
| Amendola, A; Billio, A; Bowles, KM; Chiarenza, A; Ciolli, S; Cortelezzi, A; Coscia, M; Cuneo, A; de la Serna, J; Delgado, AR; Eyre, TA; Farina, L; Foà, R; Follows, G; Forconi, F; Gaidano, G; Galieni, P; Ghia, P; Gonzalez, M; Ilariucci, F; Kennedy, B; Laurenti, L; Marasca, R; Marchetti, M; Mauro, FR; Meneghini, V; Molica, S; Montillo, M; Moreno, C; Musuraca, G; Orlandi, EM; Perez, AM; Piciocchi, A; Re, F; Rigolin, GM; Schuh, A; Smolej, L; Tedeschi, A; Trentin, L; Vignetti, M; Visco, C | 1 |
| Allen, J; Badillo, M; Lee, HJ; Ok, CY; Prabhu, V; Romaguera, JE; Sadimin, ET; Schalop, L; Schenkel, J; Tarapore, R; Wang, M; Zloza, A | 1 |
| Brown, JR | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Doll, D; Letendre, P | 1 |
| Abramson, JS; Barr, PM; Bartlett, NL; Blachly, JS; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Fruth, B; Heerema, NA; Hurria, A; Kuzma, C; Larson, RA; Little, RF; Litzow, M; Lozanski, G; Major-Elechi, B; Mandrekar, SJ; Nattam, S; Owen, C; Ozer, HG; Parikh, SA; Rogers, KA; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA; Zhao, W | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, BF; Estenfelder, S; Fink, AM; Fischer, K; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Heinz, WJ; Hensel, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Pflug, N; Ritgen, M; Robrecht, S; Sasse, S; Stilgenbauer, S; Tausch, E; Tresckow, JV; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Connor, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, GAM; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Loscertales, J; Mato, A; Mayer, J; Nottage, K; Pavlovsky, MA; Rule, S; Salman, M; Samoilova, O; Santucci Silva, R; Schuier, N; Sun, S; Tamegnon, M | 1 |
| Allan, JN; Barr, PM; Billio, A; Brander, DM; Cavallari, M; Cimino, G; Coscia, M; Cucci, R; Cuneo, A; de la Serna, J; Di Raimondo, F; Doubek, M; Farina, L; Ferrarini, I; Foà, R; Gaidano, G; Gentile, M; Ghia, P; Hill, BT; Ilariucci, F; Jacobs, R; Lamanna, N; Lansigan, F; Laurenti, L; Marchetti, M; Mato, AR; Mauro, FR; Medina Perez, A; Molica, S; Orlandi, EM; Pagel, JM; Piciocchi, A; Pu, JJ; Rigolin, GM; Roeker, L; Schuster, SJ; Sehgal, AR; Shadman, M; Shah, NN; Skarbnik, AP; Spacek, M; Tam, CS; Tedeschi, A; Trentin, L; Ujjani, CS; Vignetti, M; Winter, A | 1 |
| Byfield, SD; Kabadi, SM; LE, L; Olufade, T | 1 |
| Choudhry, A; Irwin, D; Thompson, S; Wilson, K | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Al-Janazreh, H; Angeletti, I; Biagi, A; Bomben, R; Bossio, S; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Menichini, P; Moia, R; Monti, P; Morabito, F; Murru, R; Neri, A; Olivieri, J; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Al-Sawaf, O; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Langerbeins, P; Pelzer, BW; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA | 1 |
| Abdel-Samad, N; Booth, AM; Chen, BE; Cheung, MC; Couban, S; Crump, M; Fraser, GAM; Hay, AE; Lam, S; Mandrekar, SJ; McDonald, G; Mittmann, N; Owen, C; Prica, A; Ruppert, AS; Shepherd, LE; Sperlich, C; van der Jagt, R; Woyach, JA; Yen, H | 1 |
| Castillo, JJ; Sarosiek, S; Treon, SP | 1 |
| Belada, D; Boccomini, C; Deshpande, S; Dreyling, M; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Henninger, T; Hermine, O; Hernández-Rivas, JÁ; Hong, X; Howes, A; Jerkeman, M; Jurczak, W; Kim, SJ; Le Gouill, S; Lewis, D; Mishima, Y; Özcan, M; Perini, GF; Pocock, C; Qin, R; Song, Y; Spurgeon, SE; Storring, JM; Trotman, J; Walewski, J; Wang, ML; Zhu, J; Zinzani, PL | 1 |
| Cuker, A; Dhopeshwarkar, N; Hennessy, S; Leonard, CE; Rhodes, JM; Yang, W | 1 |
| Al-Sawaf, O; Böttcher, S; Cramer, P; Eichhorst, BF; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Cliff, ERS; Dickinson, M | 1 |
| Birtas Atesoglu, E; Ferhanoglu, B; Ozbalak, M | 1 |
| Eşkazan, AE | 1 |
| Dreyling, M; Le Gouill, S; Wang, ML | 1 |
| Sheng, Z; Wang, L | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
| Caces, DB; Curtis, M; Danielewicz, I; Freeman, J; García-Sancho, AM; Glazunova, V; Grigg, A; Henninger, T; Hess, G; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; McKay, P; Merli, F; Munakata, W; Nagai, H; Nastoupil, LJ; Özcan, M; Pavlovsky, MA; Preis, M; Qin, R; Rowe, M; Salles, G; Tamegnon, M; Thieblemont, C; Wang, T | 1 |
| Afzali, M; Faraji, H; Fariman, S; Momeni Nasab, F | 1 |
| Chen, X; Hong, Y; Huang, Z; Mi, J; Wang, Y; Xiao, X; You, X; Zheng, P; Zhou, T | 1 |
11 review(s) available for bendamustine hydrochloride and pci 32765
| Article | Year |
|---|---|
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Humans; Immunotherapy; Mutation; Myeloid Differentiation Factor 88; Piperidines; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2016 |
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Everolimus; Humans; Myeloid Differentiation Factor 88; Piperidines; Plasma Exchange; Pyrazoles; Pyrimidines; Retreatment; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia | 2017 |
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2021 |
Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Network Meta-Analysis; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2023 |
15 trial(s) available for bendamustine hydrochloride and pci 32765
| Article | Year |
|---|---|
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2015 |
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Young Adult | 2015 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Thrombocytopenia | 2016 |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Physical Fitness; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Rituximab; Surveys and Questionnaires | 2018 |
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Young Adult | 2019 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Survival Analysis | 2018 |
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2019 |
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Treatment Outcome | 2021 |
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2020 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Hypertension; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Rituximab; Survival Rate | 2021 |
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prospective Studies; Rituximab; Survival Analysis; Treatment Outcome | 2021 |
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Survival Analysis | 2022 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Piperidines; Prednisone; Rituximab; Vincristine | 2023 |
33 other study(ies) available for bendamustine hydrochloride and pci 32765
| Article | Year |
|---|---|
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Blood Platelets; Chemical Precipitation; Cryoglobulins; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Piperidines; Platelet Count; Pyrazoles; Pyrimidines; Rituximab; Thrombocytopenia | 2015 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Discovery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; San Francisco; Societies, Medical | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Cell Activating Factor; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Expression Regulation, Leukemic; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Cells, Circulating; Nitrophenols; Piperazines; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Combo Therapy Effective for Relapsed CLL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Standard of Care; Treatment Outcome | 2015 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Topics: Adenine; Bendamustine Hydrochloride; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Female; Follow-Up Studies; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcriptome; Tumor Cells, Cultured | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Topics: Adenine; Advisory Committees; Antineoplastic Agents; Australia; Bendamustine Hydrochloride; Bone Marrow; Bortezomib; Humans; Immunoglobulin M; Mutation; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Rituximab; Societies, Medical; Waldenstrom Macroglobulinemia | 2017 |
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Health Resources; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Econometric; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Survival Analysis | 2017 |
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; United Kingdom | 2018 |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; United Kingdom | 2018 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dopamine D2 Receptor Antagonists; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Male; Molecular Targeted Therapy; Neoplasm Proteins; Oligopeptides; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Rituximab; Stress, Physiological; Vincristine | 2019 |
Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
Topics: Adenine; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; United Kingdom | 2018 |
Novel therapeutics in the treatment of hairy cell leukemia variant.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2018 |
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Bone Marrow; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Europe; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Rituximab; Time Factors; United States | 2020 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Doxorubicin; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Prednisone; Renal Insufficiency; Retrospective Studies; Rituximab; Stroke; Vincristine | 2021 |
Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Topics: Adenine; Bendamustine Hydrochloride; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient Acceptance of Health Care; Piperidines; Retrospective Studies; Rituximab | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Topics: Adenine; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Rituximab | 2021 |
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma. Reply.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran.
Topics: Aged; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Iran; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab | 2023 |
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53 | 2023 |